Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3644477
Max Phase: Preclinical
Molecular Formula: C17H23N5O
Molecular Weight: 313.40
Molecule Type: Small molecule
Associated Items:
ID: ALA3644477
Max Phase: Preclinical
Molecular Formula: C17H23N5O
Molecular Weight: 313.40
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)c1ccccc1N1CCN(C(=O)c2nc[nH]n2)CC1
Standard InChI: InChI=1S/C17H23N5O/c1-17(2,3)13-6-4-5-7-14(13)21-8-10-22(11-9-21)16(23)15-18-12-19-20-15/h4-7,12H,8-11H2,1-3H3,(H,18,19,20)
Standard InChI Key: ZBRVJOIEFQDRHB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 313.40 | Molecular Weight (Monoisotopic): 313.1903 | AlogP: 2.06 | #Rotatable Bonds: 2 |
Polar Surface Area: 65.12 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.88 | CX Basic pKa: 3.41 | CX LogP: 2.97 | CX LogD: 2.97 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.92 | Np Likeness Score: -1.50 |
1. (2014) Derivatives of N-acyl-N‚Ä=-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes, |
Source(1):